S

SymBio Pharmaceuticals Ltd
TSE:4582

Watchlist Manager
SymBio Pharmaceuticals Ltd
TSE:4582
Watchlist
Price: 86 JPY -2.27% Market Closed
Market Cap: ¥4.8B

Operating Margin

-290.1%
Current
Declining
by 201.1%
vs 3-y average of -89%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-290.1%
=
Operating Income
¥-4.4B
/
Revenue
¥1.5B

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-290.1%
=
Operating Income
¥-4.4B
/
Revenue
¥1.5B

Peer Comparison

Country Company Market Cap Operating
Margin
JP
SymBio Pharmaceuticals Ltd
TSE:4582
4.5B JPY
Loading...
US
Eli Lilly and Co
NYSE:LLY
972.2B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
547.5B USD
Loading...
CH
Roche Holding AG
SIX:ROG
277.1B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
209.4B GBP
Loading...
CH
Novartis AG
SIX:NOVN
219B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
272.1B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
148.3B USD
Loading...
FR
Sanofi SA
PAR:SAN
93.8B EUR
Loading...

Market Distribution

Lower than 99% of companies in Japan
Percentile
1st
Based on 6 730 companies
1st percentile
-290.1%
Low
-125 500% — 4.2%
Typical Range
4.2% — 10.6%
High
10.6% — 9 743.7%
Distribution Statistics
Japan
Min -125 500%
30th Percentile 4.2%
Median 7%
70th Percentile 10.6%
Max 9 743.7%

SymBio Pharmaceuticals Ltd
Glance View

Market Cap
4.8B JPY
Industry
Pharmaceuticals

SymBio Pharmaceuticals Ltd. engages in the pharmaceutical business. The company is headquartered in Minato-Ku, Tokyo-To and currently employs 141 full-time employees. The company went IPO on 2011-10-20. Along with medicine specialists, contract research organizations (CROs) and other pharmaceutical companies, the Company is engaged in the design and operation of clinical tests, the manufacture and sale of new drugs specializing in three therapeutic areas: cancer, blood diseases and autoimmune diseases. The firm develops new medicines using chemical compounds proofed by preclinical tests and clinical tests. The firm manufactures and sells medicines through domestic and foreign pharmaceutical companies. The firm's pipelines include anticancer drugs, such as SyB L-0501, SyB L-1101 and SyB C-1101.

SymBio Pharmaceuticals Ltd Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-290.1%
=
Operating Income
¥-4.4B
/
Revenue
¥1.5B
What is SymBio Pharmaceuticals Ltd's current Operating Margin?

The current Operating Margin for SymBio Pharmaceuticals Ltd is -290.1%, which is below its 3-year median of -89%.

How has Operating Margin changed over time?

Over the last 3 years, SymBio Pharmaceuticals Ltd’s Operating Margin has decreased from 21.7% to -290.1%. During this period, it reached a low of -290.1% on Oct 30, 2025 and a high of 21.7% on Aug 30, 2022.

Back to Top